Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX)
Rhea-AI Filing Summary
Protagonist Therapeutics Inc Schedule 13G filing reports that Vanguard Portfolio Management beneficially owned 3,533,015 shares of Common Stock, representing 5.53% of the class as of 03/31/2026. The filer states sole dispositive power over the 3,533,015 shares and sole voting power for 51,804 shares. The filing is signed on 04/29/2026 by a Vanguard official.
Positive
- None.
Negative
- None.
Insights
Vanguard holds a >5% passive stake in Protagonist as of 03/31/2026.
Vanguard Portfolio Management reports beneficial ownership of 3,533,015 shares (5.53%), indicating it is a large institutional holder under Schedule 13G reporting rules. The filing lists 51,804 shares with sole voting power and 3,533,015 shares with sole dispositive power.
As a Schedule 13G disclosure, this typically reflects passive investment intent. Future Form 13D/13G amendments could change characterization; subsequent filings will show any active acquisition or disposition activity.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Sole dispositive power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.